Intelligent Uterine Fibroid Treatment System
Legal Citation
Summary of the Inventive Concept
A comprehensive system integrating collagenase-based treatment with AI, IoT, and blockchain technologies to provide personalized, optimized, and secure uterine fibroid treatment.
Background and Problem Solved
Uterine fibroids affect millions of women worldwide, with current treatments often ineffective or invasive. The original patent's collagenase-based treatment method has limitations in terms of treatment efficacy, dosage optimization, and data tracking. The new inventive concept addresses these limitations by incorporating synergistic technologies to create a more powerful system.
Detailed Description of the Inventive Concept
The system comprises a collagenase-based treatment composition, a blockchain-based tracking module for monitoring treatment efficacy, and a machine learning algorithm for predicting optimal treatment dosages based on patient-specific characteristics. The system can also include IoT-enabled sensors for tracking treatment outcomes and wearable devices for patient monitoring. The AI-powered analytics engine analyzes treatment data, and a visualization dashboard presents treatment outcomes to healthcare providers.
Novelty and Inventive Step
The new claims introduce a synergistic combination of distinct technologies, creating a novel system that overcomes the limitations of the original patent. The integration of AI, IoT, and blockchain technologies with collagenase-based treatment provides a non-obvious solution for personalized and optimized uterine fibroid treatment.
Alternative Embodiments and Variations
Alternative embodiments may include using different types of sensors or wearable devices, integrating additional AI-powered predictive models, or incorporating other blockchain-based data storage modules. Variations may also include adapting the system for treating other types of fibroids or tumors.
Potential Commercial Applications and Market
The Intelligent Uterine Fibroid Treatment System has significant commercial potential in the healthcare industry, particularly in the fields of women's health, oncology, and medical technology. The system's ability to provide personalized and optimized treatment, combined with its secure data tracking and analytics capabilities, makes it an attractive solution for healthcare providers and patients alike.
CPC Classifications
| Section | Class | Group |
|---|---|---|
| A | A61 | A61K9/48 |
| A | A61 | A61K9/0019 |
| A | A61 | A61K9/0034 |
| A | A61 | A61K9/1075 |
| A | A61 | A61K38/43 |
| A | A61 | A61K38/4886 |
| A | A61 | A61K45/06 |
| C | C12 | C12Y304/24003 |
Section 103 Obviousness Analysis (PHOSITA)
Field of Art
Medical biotechnology, specifically interventional treatment of uterine fibroids using enzymatic compositions, involving interdisciplinary technologies including AI, IoT, and blockchain medical tracking systems
Person of Ordinary Skill (PHOSITA) Profile
A medical professional with expertise in interventional medicine, biotechnology, and digital health technologies, possessing advanced knowledge of medical device design, treatment optimization algorithms, and data management systems
Obviousness Rationale
A PHOSITA would recognize that integrating digital tracking and optimization technologies with established medical treatment methodologies represents a predictable extension of existing medical innovation strategies. The combination of collagenase-based treatment with AI-driven personalization and blockchain tracking follows established patterns of technological convergence in medical treatment systems. The technical elements disclosed in the PTD represent incremental improvements that leverage known technologies to enhance existing treatment protocols.
Obvious Combinations & Variations
Original Patent Information
| Patent Number | US 11,857,685 |
|---|---|
| Title | Treatment method and product for uterine fibroids using purified collagenase |
| Assignee(s) | Duke University, BioSpecifics Technologies LLC |